Titles
- Drug manufacturing: FDA should fully assess its efforts to encourage innovation : report to congressional committees1
- Drug misuse: agencies have not fully identified how grants that can support drug prevention education programs contribute to national goals : report to Congress1
- Drug misuse: sustained national efforts are necessary for prevention, response, and recovery : report to the Congress1
- Drug name suffix confusion is a common source of errors1
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Drug product tracing: the effect of section 585 of the FD&C Act : questions and answers1
- Drug products, including biological products, that contain nanomaterials1
- Drug safety: COVID-19 complicates already challenged FDA foreign inspection program : testimony before the Committee on Finance, U.S. Senate1
- Drug safety: FDA should take additional steps to improve its foreign inspection program : report to congressional requesters1
- Drug safety: preliminary findings indicate persistent challenges with FDA foreign inspections : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Drug shortages: shortchanging quality and safe patient care1
- Drug supply chain security: dispensers received most tracing information1
- Drug supply chain security: wholesalers exchange most tracing information1
- Drug-drug interaction assessment for therapeutic proteins: guidance for industry1
- Drug-free community support program: agencies have strengthened collaboration but could enhance grantee compliance and performance monitoring : report to Congressional committees1
- Drugs against cancer: stories of discovery and the quest for a cure1
- Drugs for treatment of partial onset seizures: full extrapolation of efficacy from adults to pediatric patients 2 years of age and older1
- Du bist nicht allein: mach mit!1
- Dual Medicare-Medicaid enrollment and integrated plan identification: T-MSIS analytic files data quality1